Ahmed Faisal, Ashraf Anas Zytoon, Abdel-Naser Gad Allah and Alaa Dawood. Predictors of Early Virological Response of Viral Hepatitis C to Combination Therapy with Pegylated Interferon Plus Ribavirin.
. 2013; 1(4):54-60. doi: 10.12691/AJCMR-1-4-3
predictors of early virological, viral hepatitis C, combination therapy, pegylated interferon
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | Lauer G.M, Walker B.D. Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41-524. |
|
[2] | Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well? Ann Intern Med 2004; 140: 370-81. |
|
[3] | Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010 Sep;105(9):1970-7. |
|
[4] | Egypt Demographic and Health Survey 2011. Cairo, Egypt: Ministry of Health. |
|
[5] | Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107. |
|
[6] | McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492. |
|
[7] | Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432. |
|
[8] | Reichard O, Norkrans G, Fryden A, Brachonier JH, Sonnerborg A, Weiland O: Randomized double blind, placebo controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet 1998, 351:83-7. |
|
[9] | Di Bisceglie et al., 2007Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. 2007;Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat, 14:721-9. |
|
[10] | Sim KH, Wojccik JP, Margulies M, Wade J, Heathcote J: Human leukocyte antigen class II alleles may affect response of chronic hepatitis C to interferon therapy. J Viral Hepat 1998, 5:249-253. |
|
[11] | Davis GL, Lau JY: Factorespredictive of beneficial response to therapy of hepatitis C. Hepatology 1997, 26(3 Suppl 1):122S-127S. |
|
[12] | Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J: Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pre-treatment variable. Gut 1993, 34:1714-1717. |
|
[13] | Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y: Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998, 158:177-181. |
|
[14] | Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht KJ: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-965. |
|
[15] | Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, Bain V: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432. |
|
[16] | Wazir MS, Majid AS, Solangi GA, Zuberi BF: Role of interferon and interferon plus ribavirin in the management of chronic hepatitis C. J CollPhysSurgeo, Pak 2002, 12:609-612. |
|
[17] | Shafi MS, Ahmad SI, Rehana M, et al.: Daily interferon versus interferon TIW in combination with ribavirin for treatment of chronic hepatitis C. JRMC 1999, 31:20-2. hepatitis C. Aliment PharmacolTher 2010; 31: 1251-67. |
|
[18] | Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well? Ann Intern Med 2004;140: 370-381. |
|
[19] | Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44. |
|
[20] | Durante-Mangoni E, Zampino R, Portella G, et al. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. ClinInfect Dis 2009; 10: 43-9. |
|
[21] | Yu ML, Dai CY, Huang JF, et al. Rapid virologic response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93. |
|
[22] | Poordad FF. Review article: the role of rapid virological response in determining treatment duration for chronic. |
|
[23] | boback D.The next era of HCV antiviral therapy. Current Infections rep.2010:12(2):79-80.1-Leiveven J: Pegasys/RBV Improves Fibrosis in Responders, relapsers & Nonresponders with Advanced Fibrosis. In 55th Annual Meeting of the American Association for the Study of Liver Disease: 2004 October 29–November 2. Boston, MA, USA; |
|
[24] | Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res, 2003; 59: 1-11. |
|
[25] | Manns M, McHutchison J and Gordon S. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001; 358:958-65. |
|
[26] | Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G and Gonçales FL Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 2002; 347(13):975-82. |
|
[27] | Zeuzem S, Buti M and Ferenci P. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol, 2006; 44:97-103. |
|
[28] | Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boye N, Ripault MP, Paradis V, Vidaud M, Valla D, Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-423. |
|
[29] | Fattovich, L. Covolo, S. Bibert, G. Askarieh, M. Lagging, S. Santantonio, and G. Raimondo. IL28B Polymorphisms, IP-10 and Viral Load Predict Virological Response to Therapy in Chronic Hepatitis C. Alimentary Pharmacology & Therapeutics 2011, 33(10):1062-1072. |
|
[30] | 30-Berg T, Weich V and Teuber G. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009, 50:369-77. |
|
[31] | Abdoul H, Mallet V, Pol S, Fontanet A. Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype. PLoS ONE 2008; 3(6): e2391. |
|
[32] | Kamal S M, Graham C S, He Q, Bianchi L, Tawil A A, Rasenack J W. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosomamansonico infection: relation to pro-gression of liver fibrosis. J Infect Dis, 2004; 189:1140-1150. |
|
[33] | Kamal S M, Madwar M A, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000, 32:172-174. |
|
[34] | Pérez Roldán F, De Diego A, Casado M, Matilla A, Bañares R, García-Durán F, Salcedo M, Cos E, Clemente G. Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment. Rev EspEnferm Dig 1996, 88(9):609-15. |
|
[35] | 35-Pockros P J, Hamzeh F M, Martin P, Lentz E, Zhou X, Govindarajan S. Histologic Outcomes in Hepatitis C Infected Patients with Varying Degrees of Virologic Response to Interferon-Based Treatments. Hepatology 2010; 52(4):1193-1200. |
|
[36] | Hosogaya S, Ozaki Y, Enomoto N, Akahane Y. ;Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C. Transl Res, 2006 148(2):79-86. |
|
[37] | Madwar M, Bianchi L, Tawil A E, Fawzy R, Peters T. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000, 20:281-289. |
|
[38] | Balart L, Lee S S, Everson GT, Reindollar R W, Shiffman M L, Minuk G Y. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008, 27:542-551. |
|
[39] | Everson G T, Jensen D M, Craig J R, van Leeuwen D J, Bain V G, Ehrinpreis M N. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. HEPATOLOGY 1999, 30:271-276. |
|
[40] | Shiffman M L, Hofmann C M, Thompson E B, Gonzalez F, Contos M J, Koshy A and Luketic A V. Relationship Between Biochemical, Virological, and Histological Response During Interferon Treatment of Chronic Hepatitis C. Hepatology, 1997; 26:780-785. |
|
[41] | Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch J H, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23: 1334-1340. |
|
[42] | Yee LJ, Im K, Borg B, Yang H, Liang TJ. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun 2009; 10:365-372. |
|
[43] | Gao B. Cytokines, STATs and liver disease. Cell MolImmunol. 2005;2(2):92-100. |
|
[44] | Banner BF, Barton AL, Cable EE, Smith L and Bonkovsky HL.A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol, 1995; 8: 232-238. |
|
[45] | Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432. |
|
[46] | Romero-Gómez M, Salmerón J, Diago M, Grande L and Vázquez L. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005,128: 636-641. |
|
[47] | Petta S, Cammà C and Di Marco V. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. AntivirTher 2009, 14: 631-9. |
|
[48] | Bortoletto G, Scribano L and Realdon S. Hyperinsulinaemia reduces the virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 2010; 17: 475-80. |
|
[49] | Alaei M and Negro F. Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab 2008, 34: 692-700. |
|
[50] | Persico M, Capasso M, Persico E, Svelto M, Russo R, Tiribelli C and Iolascon A; Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007, 46: 1009-1015. |
|